Immene cell engaging bispecific antibody for
mCRPC (Metastatic Castration-Resistant Prostate Cancer)

AM109 is an AffiMab-based bispecific antibody that kills tumor cells by binding to both T cells and tumor cells.

  • AM109
  • AM109 has tumor cell specific immune cell activation mechanism by targeting to both
    CD137 (4-1BB) on immune cells and PSMA on mCRPC. Using AffiMab format designed to
    exert optimal activation of immune cells, it is expected to have efficient tumor cell killing
    with low toxicity and long-lasting efficacy.
Designed by CHAIRONE
© AbClon. All rights reserved.